Ruben Raychaudhuri

The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. Omar Mian discusses: Metastasis-directed Therapy in Prostate Cancer.

Exciting to see the trial I wrote at @ASCO @AACR #VailWorkshop2019 published. Thanks to mentor @PGrivasMDPhD and for the team @fredhutch carrying this through to completion! #PDG6

Prostate Cancer: A Review jamanetwork.com/journals/jama/… via @RubenRaychaud et al

Ab#769 @ASCO #GU25  👉Congrats @RubenRaychaud @PGrivasMDPhD👉bit.ly/3EqFDsD👉Ph2 trial of neoadj pembro + aMVAC in pts w/ non-urothelial MIBC #bladdercancer👉pCR 53%, median EFS 38 mos & median OS NR👉Promising data👇 @OncoAlert @urotoday @BladdercancerUS

Please do read our letter to editor to @JCO_ASCO with regards to the recent publication of the ARANOTE trial. Until when shall we put up with inferior control arms? Congratulations @abhenilmittal for raising awareness re this important issue. ascopubs.org/doi/10.1200/JC…

Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial by @RubenRaychaud et al. Full article: europeanurology.com/article/S0302-…

#PLATIPARP: A phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in treatment of pts with #mCRPC with homologous recombination DNA repair deficiency @RubenRaychaud @fredhutch. #ASCO24 written coverage by @rksayyid > bit.ly/4e30T59

💫🌟#Genomic Correlates of Prostate-Specific Membrane Antigen #PSMA Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study🌟💫 @OncoAlert @PGrivasMDPhD @JessicaHawleyMD @RubenRaychaud @LauraGrahamMD @ColinCPritchard @PCFnews @PCF_Science ascopubs.org/doi/10.1200/PO… 🔷️Purpose of the Study 🔹️ To evaluate the association between the mutational profile of metastatic castration-resistant prostate cancer (mCRPC) and the clinical efficacy of treatment with 177Lu-PSMA-617 (LuPSMA). 🔷️Methodology 🔹️ Retrospective multicenter analysis of 126 mCRPC patients who received LuPSMA and had next-generation sequencing (NGS) results. 🔹️ Comparison of treatment response, prostate-specific antigen progression-free survival (PSA PFS), and overall survival (OS) among genetically defined subgroups. 🚨Key Findings 🔹️ Presence of tumor suppressor gene (TSG) mutations was associated with shorter PSA PFS and OS. 🔹️Patients with DNA damage repair (DDR) gene mutations showed improved OS in multivariable analysis. 🔹️ PSMA expression did not show significant differences between DDR-deficient and DDR-proficient cohorts. 🔹️ Patients with ATM mutations demonstrated higher treatment response rates, longer PSA PFS, and better OS. 🔹️ #BRCA2 mutations were not associated with improved clinical outcomes. 🔹️ #CDK12 mutations were associated with poorer responses and shorter PSA PFS. 🔷️Conclusions 🔹️ Variability in clinical outcomes with #LuPSMA can be influenced by the tumor's mutational profile. 🔹️ Prospective studies are warranted to better define the clinical activity of LuPSMA in predetermined genomic subgroups. 🔷️ Limitations 🔹️ Retrospective nature of the study and small sample size of genomic subgroups. 🔹️ Limitations in measuring PSMA expression across multiple sites. #GenomicMedicine #ProstateCancer #PrecisionOncology #LuPSMA #CancerResearch #mCRPC

Our #prostatecancer group led by #MahaHussain @oreganruth #ShingLee #SanfordJeames at @AACR @ASCO methods in clinical cancer research conference #MCCR23 #VailWorkshop. Such excellent trials developed in this one of a kind workshop.